The current gold standard for treatment of ovarian, primary peritoneal and fallopian tube cancers is cytoreductive surgery followed by intravenous and/or intraperitoneal chemotherapy (Hennessy 2009). Studies have decisively shown that the outcomes of progression free survival (PFS) and overall survival (OS) have a direct correlation with complete removal of visible diseased tissue (complete cytoreduction) or removal of diseased tissue to
The study discussed here has collected eight-years (July 2007-December 2014)
of surgical outcome data for women with epithelial ovarian, primary peritoneal and fallopian tube cancers undergoing cytoreductive surgery at John Muir Health. This analysis is to monitor if our program is achieving outcomes that have been shown to be directly related to progression free survival (PFS) and overall survival (OS) in the literature. Therefore, complete or optimal cytoreduction will be used as a surrogate end-point.